Separately, NICE, in their guidance recommend encorafenib with binimetinib, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults only if the company provides encorafenib and binimetinib according to commercial arrangements.